Table 3 Measurement of PRDX2 autoantibody, PRDX3 autoantibody and their combination of VCA-IgA in NPC diagnosis
| Â | AUC (95% CI) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | PLR | NLR |
|---|---|---|---|---|---|---|---|
NPC versus NC | |||||||
 PRDX2 autoantibody | 0.614 (0.542–0.686) | 26.4 | 96.0 | 89.5 | 50.3 | 6.60 | 0.77 |
 PRDX3 autoantibody | 0.600 (0.528–0.673) | 24.5 | 95.0 | 86.3 | 49.4 | 4.90 | 0.79 |
 PRDX2 autoantibody + PRDX3 autoantibody | 0.632 (0.561–0.703) | 36.4 | 95.0 | 90.4 | 53.7 | 7.28 | 0.67 |
 VCA-IgA | 0.719 (0.653–0.785) | 48.8 | 95.0 | 92.6 | 59.0 | 9.76 | 0.54 |
 Autoantibody + VCA-IgA | 0.811 (0.753–0.869) | 66.7 | 95.0 | 94.5 | 68.9 | 13.34 | 0.35 |
Early-stage NPC versus NC | |||||||
 PRDX2 autoantibody | 0.642 (0.532–0.753) | 27.5 | 96.0 | 73.4 | 76.8 | 6.88 | 0.76 |
 PRDX3 autoantibody | 0.646 (0.537–0.755) | 25.0 | 95.0 | 66.7 | 76.0 | 5.00 | 0.79 |
 PRDX2 autoantibody + PRDX3 autoantibody | 0.664 (0.550–0.779) | 40.0 | 95.0 | 76.2 | 79.8 | 8.00 | 0.63 |
 VCA-IgA | 0.638 (0.528–0.747) | 32.5 | 95.0 | 72.3 | 77.8 | 6.50 | 0.71 |
 Autoantibody + VCA-IgA | 0.754 (0.652–0.857) | 50.0 | 95.0 | 80.0 | 82.6 | 10.00 | 0.53 |